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Discriminant analysisComplex diseases result from contributions of multiple genes that act in concert through pathways. Here we
present a method to prioritize novel candidates of disease-susceptibility genes depending on the biological
similarities to the known disease-related genes. The extent of disease-susceptibility of a gene is prioritized
by analyzing seven features of human genes captured in H-InvDB. Taking rheumatoid arthritis (RA) and pros-
tate cancer (PC) as two examples, we evaluated the efﬁciency of our method. Highly scored genes obtained
included TNFSF12 and OSM as candidate disease genes for RA and PC, respectively. Subsequent characteriza-
tion of these genes based upon an extensive literature survey reinforced the validity of these highly scored
genes as possible disease-susceptibility genes. Our approach, Prioritization ANalysis of Disease Association
(PANDA), is an efﬁcient and cost-effective method to narrow down a large set of genes into smaller subsets
that are most likely to be involved in the disease pathogenesis.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Finding disease-causing genes is one of the major issues in the
human genome studies. The use of linkage analysis and positionaltion Research Center, National
y, 2-4-7 Aomi, Koto-ku, Tokyo
, tgojobor@genes.nig.ac.jp
, 1-7-22 Suehirocho, Tsurumi,
rights reserved.cloning techniques has led to the identiﬁcation of genes involved in nu-
merous Mendelian genetic disorders [1–4]. However, ﬁnding causative
genes for complex disorders is more challenging. Multiple genes con-
tribute to the pathogenesis of common disorders and each gene may
contribute to a different degree. Therefore, association studies to detect
genes contributing to complex diseases are designed by recruiting
large numbers of subjects and genotyping many polymorphic markers.
The possible susceptible loci identiﬁed by association studies usually
contain dozens of candidate disease genes. Further studies identifying
causative variants and characterizing biological processes of disease-
onset mechanism require additional substantial resources, and can be
impractical when examining dozens of genes. Even if genome-wide
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polymorphic markers, a fraction of markers showing statistically signif-
icant associations may be false positive. In ﬁnding genes involved in the
disease pathogenesis, it is not easy to distinguish biological relevance
from the false positives in studies with a large number of markers.
Thus, a method to prioritize candidate disease genes based on a priori
biological knowledge is useful to narrow down candidate genes to
identify causative genes of common diseases.
Cataloguing human genes [5–7] and annotations enabled us to an-
alyze biological information of human genes in various ways. One im-
portant application has been to prioritize possible candidate genes of
disease implication by evaluating similarity or interactions between
genes that have not only sequence homology but also share functional
information including biological pathways. Recent studies showed
that related phenotypes share common genetic basis and susceptibil-
ity genes [8–10] because the proteins involved in the pathogenesis are
likely to interact together [11,12] in a few biological pathways. Al-
though there are previous studies on prioritizing disease-related
genes by use of biological information [13–20], using various kinds
of biological information of human genes would be useful. Therefore,
we developed a method to prioritize candidate genes for common dis-
eases by utilizing biological information of human genes. Our method
depends on two assumptions: (1) genes related to a particular disease
often have common inherent structural and functional properties, and
(2) known causative genes of a particular disease and novel candidate
genes for the disease may share speciﬁc biological pathways or sub-
cellular locations of gene products. The analysis starts with collection
and curation of known related genes for the target disease. We ana-
lyze enrichment of biological functions in known related genes for
the target disease, by using biological terms of functional domains
from InterPro (www.ebi.ac.uk/interpro/), Enzyme Commission (EC)
numbers (www.chem.qmul.ac.uk/iubmb/enzyme/), biological path-
ways from the Kyoto Encyclopedia of Genes and Genomes (KEGG)
(www.genome.ad.jp/kegg/) [21], and Gene Ontology (GO) (www.
geneontology.org/) [22]. Then we examine all the other genes one
by one whether a gene is biologically closer to the known related
genes for the target disease than to the other genes by a subsequent
discriminant analysis. Finally, we obtain a prioritized list of candidate
genes for the disease.
We applied our approach to rheumatoid arthritis (RA) and prostate
cancer (PC) in order to evaluate its efﬁciency. RA is the most common
disabling autoimmune disease, affecting approximately 0.3–1% of the
population [23]. While the etiology and pathogenesis of RA are not
completely understood, a previous report has identiﬁed candidate
genes and loci that may be related to RA [24]. Another common disease,
PC, is the most commonly diagnosed male malignancy, and is the sec-
ond leading cause of male cancer mortality in the world [25]. PC has
long been known to cluster in families [26], and both segregation and
linkage analyses have identiﬁed speciﬁc prostate cancer susceptibility
loci and candidate genes [27,28]. Thus, both RA and PC represent com-
plex genetic diseases for which the identiﬁcation of causative disease
genes would have a dramatic impact on public health.
This method, which we implemented by a system, Prioritization
ANalysis for Disease Association (PANDA), provides prioritized candi-
dates of disease-related genes that are useful for further studies to
identify of new causative genes. The resulting output of our approach
is a prioritized list of candidate genes for the diseases that represent
potential disease biomarkers and perhaps even potential targets for
therapies.
2. Results
2.1. Prioritization analysis of candidate genes for RA and PC
Known disease-related genes for RA and PC were retrieved from
OMIM database (www.ncbi.nlm.nih.gov/Omim) [29] and subsequentlychecked in Entrez Gene (www.ncbi.nlm.nih.gov/gene) by using MeSH
terms (www.nlm.nih.gov/mesh/) for the two diseases (see Methods
and Fig. 1). After manual curation, we selected 139 genes as known
RA-related genes and 296 genes as known PC-related genes (Supple-
mental Tables 1–2). These genes were used as ‘training sets’ to analyze
all other genes in theH1-REFSEQDB (an in-house database of all human
genes containing 14,959 human genes, see Methods) for likeliness of
disease susceptibility. Biological information of all human geneswas re-
trieved fromH-InvDB, and seven biological features (paralogy, InterPro,
EC number, biological pathways from KEGG, and three categories of
Gene Ontology, seeMethods) of human geneswere used to examine bi-
ological similarity of a gene to a group of known related genes for the
target disease (group 1) or another group of all the other genes
(group 2). Then we examined whether a gene tested is closer to the
group 1 than to the group 2 by comparing theMahalanobis distance be-
tween a gene and the group 1 (MD1) with another distance between
the gene and the group 2 (MD2). We calculated the ratio of MD2 to
MD1 (PANDA score) for each gene tested. To narrow downmore prom-
ising candidate genes for the target diseases, we used a higher thresh-
old; the average values of the PANDA score for the known related
genes (21.2 for RA and 14.1 for PC). As a result, 526 geneswere detected
as candidate genes for RA and 609 genes for PC (Table 1).
2.2. Candidate genes on genomic regions of interest
Although putative susceptible loci for RA and PC have been identi-
ﬁed by linkage analysis, association study, comparative genomic hy-
bridization and chromosomal transfer, the actual genes involved in
the disease have not been identiﬁed yet for many of these genomic re-
gions. Therefore, a localization of a candidate gene on one of these geno-
mic regions of interest (GROI) provides additional support for its
potential role in the disease. To select candidate disease genes in
GROIs, we searched the GROIs in OMIM for RA and PC, and found nine
GROIs for RA and 18 GROIs for PC (listed in Supplemental Tables 3–4).
Then we selected the candidate genes that were localized within
these GROIs, and obtained 56 candidate genes for RA and 63 for PC.
2.3. Highly scored genes for rheumatoid arthritis
To further narrow down the most plausible candidate genes for RA,
we ranked the 56 candidates on the GROIs according to the discrimi-
nant analysis with the Mahalanobis distances (Supplemental Table 3).
We inspected the highly scored genes, surveyed literature and found
that these genes included biologically reasonable candidate genes. For
example, tumor necrosis factor ligand superfamily member 12
(TNFSF12) showed the third highest score in 17p13 (Table 2A) which
is one of the GROIs with RA [24]. The TNFSF12 gene shares three GO an-
notations (tumor necrosis factor receptor, immune response andmem-
brane) with other known RA-related genes, including TNF (tumor
necrosis factor), HLA-DRB1 (major histocompatibility complex,
class II, DR beta 1) and toll-like receptor 2 (TLR2) (Table 2B). The
TNFSF12 gene is expressed in macrophages, which inﬁltrates the syno-
vial membrane to form the inﬂammatory pannus that is characteristic
of RA invading joint cartilage and destroying the underlying bone.
TNFSF12 induces activation of matrix metallopeptidase 9 through nu-
clear factor of kappa light polypeptide gene enhancer in B-cells 1
(NFKB1) pathway [30] that controls the incidence of collagen-based ar-
thritis in mice through modulation of inhibitor of kappa light polypep-
tide gene enhancer in B-cells, kinase beta (IKBKB) [31,32]. In addition, a
molecule in the NFKB1 pathway, encoded by nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor-like 1(NFKBIL1),
was reported as a candidate RA-susceptibility gene, from an evidence
of a di-allelic polymorphism in the promoter region of the gene [33].
Biological annotation of TNFSF12 shows functional similarities with
some of the known RA-related genes. Thus, our result suggests that
TNFSF12 may be involved in the pathogenesis of RA.
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Fig. 1. Analysis pipeline with the Prioritization ANalysis of Disease Association (PANDA) system. Known related genes for the target disease (rheumatoid arthritis and prostate can-
cer in this study) were retrieved from OMIM and Entrez Gene, manually annotated and used as training set (group 1). We examined the proportion of biological terms in the train-
ing set and that in all human genes (H1-REFSEQ DB, see Methods). Based on different proportions of biological functions between the training set and all human genes, scores for
multiple parameters were given to the all human genes. Candidate disease-related genes were prioritized by the discriminant analysis with multiple parameters. We calculated the
Mahalanobis distances (MD1) between the position of a gene tested (open diamond) and the center of gravity of the group 1 (CG1, open circle) with multiple parameters. Similarly
the Mahalanobis distances (MD2) between each gene and the center of gravity of the group 2 (CG2, ﬁlled circle) were calculated. Then we calculated the ratio of MD2 to MD1
(PANDA score) for each gene. Using the average value of the PANDA score for the known disease genes as a threshold, we considered any gene to be a candidate gene of
disease-susceptibility if the ratio was greater than the threshold.
Table 1
Summary of prioritization analysis of disease-susceptibility genes for RA and PC.
Disease relation Predicted similarity to known disease genes RA PC
Known – 139 296
Unknown Yesa 526 609
No 14,294 14,054
Candidate genes with disease-susceptibility for rheumatoid arthritis (RA) and prostate
cancer (PC) were prioritized by analyzing biological information of human genes.
We analyzed total 14959 human genes in H1-REFSEQ DB (an in-house database of
human genes) including known related genes for the target diseases as the training
sets. Each gene was tested one by one whether the gene is more similar to the
known disease genes than the others by data-mining and discriminant analysis (see
Methods). The numbers of genes for each category are shown.
a Genes whose PANDA scores (MD2/MD1) were higher than the threshold (the me-
dian in the training set).
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Similarly, we ranked the 63 candidate genes for PC (Supplemental
Table 4) that were located in the 18 GROIs. One GROI for PC, 22q12,
has been reported to be associated with PC by a combined genome-
wide linkage scan [34]. The highly scored genes in 22q12 included
Oncostatin M (OSM) with the highest PANDA score (30.4, Table 3A).
OSM, an interleukin 6 (IL6)-type cytokine, induces activation of the
androgen receptor (AR) in the absence of androgen [35]. OSM shares
four GO annotations (cytokine activity, immune response, regulation
of cell growth, extracellular) with known PC-related genes, including
IL6, IL8, IGFBP3 and INS (Table 3B). Interestingly, AR and IL6 have been
implicated as relevant molecules for PC, and were present in the
known PC-related genes as the training set. Thus, OSM is a candidate
Table 2A
Highly scored genes within 17p13 in relation to RA.
Gene symbol Gene name Transcript PANDA score
(MD2/MD1)
No. of
GO featuresa
No. of
other featuresb
CHRNE Cholinergic receptor, nicotinic, epsilon polypeptide NM_000080 85.3 3 0
CHRNB1 Cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) BC011371 85.3 3 0
TNFSF12 Tumor necrosis factor (ligand) superfamily, member 12 NM_172089 62.1 3 0
NLGN2 Neuroligin 2 AB037787 16.2 2 2
MYH10 Myosin, heavy polypeptide 10, non-muscle AK026977 14.7 1 2
AURKB Aurora kinase B BC000442 13.6 2 3
ALOX12P2 Arachidonate 12-lipoxygenase pseudogene 2 AL832768 11.2 0 2
ALOX15 Arachidonate 15-lipoxygenase BC029032 11.2 2 3
KIF1C Kinesin family member 1C AB014606 10.5 2 2
Highly scored genes were ranked by the PANDA score (MD2/MD1).
a Number of GO features of the gene (molecular function, biological process, and cellular component).
b Number of non-GO features of the gene for four features (amino acid sequence similarity, InterPro, EC number, and KEGG pathways).
Table 2B
Scores for TNFSF12 in relation to RA.
Parameter Functional annotation ID Base
relevance
score
Proportion in gene set Score to
TNFSF12a
Training set All human genes
GO molecular function Tumor necrosis factor receptor binding GO:0005164 (6)b 2.5 0.0102 0.0011 134.85
GO biological process Immune response GO:0006955 (7) 1.77 0.2342 0.0168 173.16
GO cellular component Membrane GO:0016020 (4) 2.03 0.2714 0.2704 8.14
Among the seven parameters, details for the three concepts of GO terms are shown. The score of paralogy was 0 because TNFSF12 did not have a sequence similarity to any known
RA-related gene. The scores of InterPro, EC number and KEGG pathway were also 0.
a Scores were calculated by Eqs. (2) and (3).
b The level in a nested hierarchical vocabulary is shown in parenthesis.
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sibly through its modulation of IL6 related pathways.
2.5. Sensitivity of predicting disease-related genes
In order to evaluate the sensitivity of our approach for predicting
disease genes, we examined whether the method correctly detects
one of the known related genes for the target disease, which was
replaced in a group of genes tested. This is an application of the
leave-one-out cross-validation (LOOCV) [36], and we sequentially re-
moved one of the known related genes for the target disease from
the training set and placed it in the group of genes to be tested.
Then, we calculated a new MD2/MD1 score (PANDA score), and
checked whether the PANDA score of the removed gene was greater
than 1. As a result, 126 of 139 (90.6%) known RA-related genes had
scores greater than 1 (Supplemental Table 5). In the same way, 264
of 296 (89.2%) known PC-related genes showed higher scores than 1
(Supplemental Table 6).
2.6. Contribution of the data type to prioritize candidates of disease gene
We used the seven biological features of human genes to calculate
Mahalanobis distance between a gene and a set of genes. However, it
is not clear whether larger numbers of parameters increase the
power of prediction and what data type is more effective than the
other data. To see how the number of parameters affects the predic-
tion power, we examined the sensitivity to identify the known dis-
ease genes by the LOOCV with different numbers of parameters in
different combinations. First, we examined the sensitivity to ﬁnd a
known disease gene with seven parameters and compared the results
with only GO annotations (molecular function, biological process and
cellular component). The sensitivities by LOOCV were 74.8% (104 of
139) for the known RA genes and 72.6% (215 of 296) for the
known PC genes when only GO annotation was used (Supplemental
Tables 5–6). These sensitivities were slightly lower than that with
the seven parameters.We also examined the sensitivities to ﬁnd known disease genes for
RA in all the 120 combinations of using 2–7 parameters (Supplemental
Table 5). In identifying the known RA genes, the sensitivity was the
highest when all the seven parameters were used. Three combinations
of 5–6 parameters had high sensitivities as the seven parameters for
the RA genes (Supplemental Table 5) when at least ﬁve parameters
(InterPro, EC number and three GO concepts) were used.
The sensitivity of identifying the known PC-related genes was ex-
amined in all 120 combinations of the parameters in the same way
(Supplemental Table 6). The use of all the seven parameters showed
the second highest sensitivity for identifying the known PC-related
genes. Three combinations of 5–6 parameters were a little more sen-
sitive than the use of the seven parameters, and two combinations of
4 or 6 parameters had the same sensitivity as the seven parameters
(Supplemental Table 6). These ﬁve combinations had at least four pa-
rameters including InterPro, GO molecular function and GO biological
process in common. These results suggest that using several features
including GO would be effective for prioritization of disease-
susceptibility genes.
3. Discussion
In the past several years, several attempts have beenmade to devel-
op methods for prioritizing potential disease-susceptibility candidates
[13–15], and these are based on sequence similarities between genes
and functional annotations from Gene Ontology. Perez-Iratxeta et al.
developed a method based on the co-appearance of GO terms and
MeSH disease terms [16,17]. In contrast, Freudenberg et al. used the
clustering method to identify new disease genes [18], while Turner et
al. presented prioritization of candidate genes using statistics
(POCUS) based on the over-representation of the annotated function
for the target disease [15]. Although these methods have been relative-
ly successful, there are two problems in identifying disease-related
genes: (1) these methods strongly depend on kind of functional infor-
mation (i.e., information from GO), and (2) some frequently appearing
biological terms in human genes can be “background noise” because
Table 3A
Highly scored genes within 22q12 in relation to PC.
Gene symbol Gene name Transcript PANDA score
(MD2/MD1)
No. of
GO featuresa
No. of
other featuresb
OSM Oncostatin M NM_020530 30.4 3 0
KREMEN1 Kringle containing transmembrane protein 1 NM_032045 22.4 0 1
GAS2L1 Growth arrest-speciﬁc 2 like 1 NM_006478 20.6 1 1
TIMP3 Tissue inhibitor of metalloproteinase 3 NM_000362 17.5 0 2
LIMK2 LIM domain kinase 2 NM_005569 17.3 2 2
PIK3IP1 HGFL gene BC011049 16.6 0 1
ADRBK2 Adrenergic, beta, receptor kinase 2 NM_005160 16.4 2 2
CHEK2c CHK2 checkpoint homolog (S. pombe) NM_007194 15.5 2 2
PLA2G3 Phospholipase A2, group III NM_015715 14.5 2 2
NF2 Neuroﬁbromin 2 BC020257 11 1 2
The prioritized genes were ranked by the PANDA score (MD2/MD1).
a Number of GO features (0–3) of the gene (molecular function, biological process, and cellular component).
b Number of non-GO features (0–4) of the gene (amino acid sequence similarity, InterPro, EC number, and KEGG pathways).
c This gene was included in the training set in the subsequent analysis with new data.
Table 3B
Scores for OSM in relation to PC.
Parameter Functional annotation ID Base
relevance
score
Proportion in gene set Score to
OSMa
Training set All human genes
GO molecular function Cytokine activity GO:0005125 (5)b 2 0.0043 0.0018 23.12
GO biological process Immune response GO:0006955 (7) 2 0.0158 0.0168 107.05
Regulation of cell growth GO:0001558 (6) 2 0.0158 0.0020
GO cellular component Extracellular GO:0005576 (3) 1.63 0.1348 0.0510 12.95
Among the seven parameters, details for the three concepts of GO terms are shown. The score of paralogy was 0 because OSM did not have a sequence similarity to any known PC-
related gene. The scores of InterPro, EC number and KEGG pathway were also 0.
a Scores were calculated by Eqs. (2) and (3).
b The level in a nested hierarchical vocabulary is shown in parenthesis.
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For instance, if the training sets include genes encoding proteins that
belong to large superfamilies such as immunoglobulin-like domain
containing proteins, too many members of the same superfamily may
be prioritized as candidate genes for the disease. In order to overcome
such possible biases of these methods, we developed a robust method
in which we use multiple sources of gene annotation and leverage
training sets consisting of known disease genes. Aerts et al. constructed
Endeavour which prioritizes disease susceptibility candidate genes
[19]. However, the problem of “background noise” in the functional
termswas not resolved in their study. Using sevenmethods for compu-
tational prioritization of disease genes, Tifﬁn et al. (2006) generated a
list of nine candidate genes for type 2 diabetes (T2D) common to six
of the seven methods [20]. We have also identiﬁed three of the nine
T2D candidate genes using PANDA system (data not shown), suggest-
ing that our method can pick up reasonable candidate genes for multi-
factorial diseases.
Here, we have highlighted two examples (TNFSF12 and OSM) that
were selected with three GO annotation categories. These two genes,
TNFSF12 and OSM, had no positive scores for the other parameters
(Tables 2B and 3B). The prioritized genes included another candidate
gene for PC, kringle containing transmembrane protein 1 (KREMEN1)
with the second highest PANDA score in 22q12 (Table 3A). KREMEN1
has only two InterPro annotations that are shared with known PC-
related genes including plasminogen activator urokinase (PLAU),
plasminogen (PLG), hepatocyte growth factor (HGF), suppression of
tumorigenicity 14 (ST14), and neuropilin 1 (NRP1) (data not
shown). This suggests that a simultaneous usage of various features
of human genes with GO annotation is effective for prioritization of
disease-related genes.
To ensure that the prioritized genes are likely to be associated
with the targeted disease, we surveyed subsequent reports in which
a causative link to disease is shown. Interestingly, Godoy-Tundidor
et al. reported that IL6 and OSM stimulate proliferation of prostatecancer cells, at least in part, through activation of the phosphatidyli-
nositol 3-kinase signaling pathway [37]. Therefore, OSM, one of the
predicted candidate genes for PC, may be a reasonable candidate
gene. We checked if there is any newly reported gene with suscepti-
bility to RA or PC by searching for the later releases of the public da-
tabases (OMIM, Entrez GENE, and PubMed). Then we prepared lists
of known related genes for RA and PC again with new data. Between
August 2004 and January 2008, 40 genes were newly described as
RA-related genes in the OMIM database (Supplemental Table 7).
When we conducted PANDA analysis by using this enhanced training
set, eight genes of the 40 genes were selected in the training set via
Entrez Gene. Three genes (FLT1, IL1RN and EBI3) of the remaining 32
genes were identiﬁed as candidate RA-susceptibility genes by our
PANDA analysis (PANDA score>21.2, Supplemental Table 7). Howev-
er, the LGALS3 gene encoding galectin-3 was not highly scored al-
though some galectin superfamily members are involved in
pathogenesis of RA. This may be because that the gene data for galec-
tin proteins had little functional annotation. One of limitations of our
approach is that genes with little annotation are less likely to be pri-
oritized as candidate disease genes. The highly scored genes included
FLT1 (PANDA score=115.5) whose gene product, FLT1, inhibits vas-
cular endothelial growth factor (VEGF) response. The VEGF response
may be involved in the pathogenesis of RA, because De Bandt et al.
found that VEGFA, FLT1, and KDR are expressed in synovial cells
from arthritic joints, using a transgenic mouse model of RA and anti-
bodies to these three proteins [38]. Another gene prioritized was
IL1RN (PANDA score=33.8) whose gene product, IL1RN, inhibits
IL1R binding by IL1-alpha and IL1-beta. Because these two cytokines
(IL1-alpha and IL1-beta) are involved in both immune response and
inﬂammatory response [39], IL1RN may be associated in the patho-
genesis for RA. Recently, new susceptible loci for RA have been
detected by GWAS [40–43], and many of them are genes involved
in immune and inﬂammatory responses. Thus our analysis may
have worked to predict biologically reasonable candidate genes.
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database between August 2004 and January 2008, and found 57 addi-
tional PC-related genes that had not been reported in 2004. Then we
conducted PANDA analysis again with the enhanced training set
(Supplemental Table 8). Among these 57 genes, 17 genes were select-
ed in the training set via Entrez Gene, and two genes, HNF1 homeo-
box B (HNF1B) and Eph receptor B2 (EPHB2), of the remaining 40
genes were identiﬁed as candidate genes by our analysis (in which
PANDA score was larger than 14.1, a threshold value in this analysis).
In particular, EPHB2 showed the second highest score (PANDA
score=40.4) among the genes that are located at 1p36.1. This gene
is of great interest because Huusko et al. identiﬁed mutations affect-
ing translation in EPHB2 in human prostate cancer cells [44]. Although
reports of new susceptible loci for PC are increasing by GWAS, analy-
sis of gene expression, and cancer genome sequencing [45–48], re-
sults of these studies include false positives. Our approach would be
useful to ﬁnd biologically relevant candidate genes from results by
such large-scale analyses.
Although we showed that our approach can predict reasonable
candidate disease genes, the approach can be extended in the follow-
ing ways. First, by including text-mining techniques, we will be able
to make enhanced training sets for other complex diseases through
automated processes. This will allow researchers to select training
sets for PANDA analysis without detailed disease-speciﬁc knowledge
or manual annotation of literature. Second, an expansion of parame-
ters (e.g. including protein–protein interaction, gene-gene interaction
and gene expression) and a customized selection of parameters
would increase the ﬂexibility of the analysis and improve the sensi-
tivity in prioritizing disease-related genes that do not have functional
similarities with known disease genes or do not have detailed func-
tional annotations. Such developments should further allow re-
searchers to leverage their knowledge base and experience to
efﬁciently prioritize disease-related candidate genes.
This approach, implemented in the PANDA system, is an efﬁcient
and cost-effective method to narrow down a large set of genes that
are typically identiﬁed in microarray or mapping studies, into a smal-
ler subset most likely to be associated with the disease. In addition,
the PANDA systemwould be a useful tool to prioritize biologically rel-
evant candidate genes with result of GWAS, large-scale gene expres-
sion data and genome sequencing to ﬁnd causative variants [49,50].
4. Methods
4.1. Data of human genes
We retrieved data of human genes from the two databases, H-InvDB
[6] and RefSeq [5]. H-InvDB (version 1.0, on 15th July 2002) contained
41,118 H-Inv cDNAs, and RefSeq contained a set of 37,488 human
mRNA sequences that were available on September 1st, 2003. After
merging the two datasets of human genes and removing the genes hav-
ing no functional information,we created theH1-REFSEQDB containing
a total of 14,959 human genes.We used representative transcripts (one
transcript for one gene) instead of all genes in H1-REFSEQDB to remove
the redundancy of cDNAs due to multiple forms of alternative splicing
variants. Information of gene structure and functional annotation for
the 14,959 human genes was retrieved from the H-InvDB [6].
4.2. Selection and curation of known related genes for the target diseases
Known related genes for the target diseases (RA and PC in this
study) were searched from the OMIM database (www.ncbi.nlm.nih.
gov/Omim) [29] and Entrez Gene (www.ncbi.nlm.nih.gov/gene), ﬁl-
tered and curated (see below), so that we can use them as the train-
ing sets of our prioritization analysis. We used MeSH terms (www.
ncbi.nlm.nih.gov/ mesh) associated with the two diseases (‘arthritis,
rheumatoid’, and ‘rheumatoid, juvenile arthritis’ for RA; ‘prostaticneoplasms’ and ‘prostatic intraepithelial neoplasia’ for PC) to scan
all abstracts of papers cited in OMIM and Entrez Gene. We obtained
231 genes as possible RA-related genes and 728 genes for possible
PC-related genes in August 2004.
Next, the two gene sets were ﬁltered to select genes that have a
series of curated references linked by PubMed IDs. We gave scores
to these known disease genes based on the associated disease MeSH
terms in their PubMed abstracts. The scores (1, 2, or 3) were assigned
automatically according to the number of major MeSH topics that an
abstract contained; no asterisk (1), asterisk for subheading (2), or as-
terisk for speciﬁc disease term (3). Then we manually annotated each
reference whether the relationship between the gene and the target
disease was mentioned by checking phenotype-speciﬁc terms. Each
abstract of the article was reviewed by two or more persons to
avoid possible problems by different interpretations and annotations
between persons. We did not weight the articles according to ap-
proaches, sample numbers or ethnicity when we annotated the dis-
ease susceptibilities of genes. The information we collected included
some genes whose role in the pathogenesis was examined in mouse
models. We did not give scores to the studies without functional val-
idation. Functionally-related genes for RA included those involved in
inﬂammation of synovial membrane, degeneration of synovial joints
or immune response. Functionally-related genes for PC included
those involved in the proliferation of cells, signal transduction and
transcription factors. After discarding genes that were not clearly re-
lated to the disease from a list of disease-related genes, we obtained
139 relevant genes for RA and 296 genes for PC (Supplemental Tables
1–2).
The selected known disease-related genes were used as the train-
ing set of the prioritization analysis with the relevance scores, which
were automatically given and manually checked (mentioned above).
Because one known disease gene may have multiple reference arti-
cles about susceptibility to the disease, we calculated wi, the arith-
metic mean of all baseline relevance scores for a particular gene i.
This wi was used as a parameter of disease susceptibility for a
known related gene for the target disease.
4.3. Analysis of biological information of known related genes for
target disease and all human genes
We selected genes that are relevant to the target disease from
OMIM and Entrez Gene by querying disease-speciﬁc MeSH terms
(downloaded on September 5, 2003). We then used these genes as
a training set to analyze biological information for prioritization of
candidates of disease-related genes. To utilize biological information
for the analysis, annotated biological information on human genes
from H-InvDB was analyzed with respect to the enrichment of speciﬁc
biological terms in the known related genes for the target disease. The
levels of enrichment of biological terms were converted into scores
using several formulae (see below). The paralogy with the known re-
lated genes for the target disease was also examined based on similar-
ity of amino acid sequence by using the BLAST program [51]. We gave
a higher score for a gene that had sequence similarity to the known
related gene for the target disease (see below). In total, we used
seven kinds of biological feature of human genes (sequence similarity,
InterPro annotation, EC number, three kinds of GO terms, and KEGG
pathways).
4.4. Sequence similarity to known related genes for the target disease:
the paralogy score
Paralogous genes that result from gene duplications have a simi-
larity in their sequence and may share some related biological fea-
tures [52]. Therefore, a paralogous gene with known disease gene
may be more likely to be involved in the disease than other genes.
Based on this concept, we calculated ‘paralogy score’ so that we give
7T. Taniya et al. / Genomics 99 (2012) 1–9a higher priority to a gene when the gene has a similarity to any
known related gene for the target disease. For this purpose, we
searched for genes that have sequence similarity to each known relat-
ed gene for the target disease. We compared amino acid sequences by
using BLAST [51], and ‘paralogous’ gene pairs were identiﬁed with
signiﬁcance cutoff values of e-100, 80, 60 and 40. When a gene i (no
previous evidence of linkage to the disease) has a similarity to
known disease gene i′, the paralogy score Sp,i of a gene i (no previous
evidence of linkage to the disease) has a positive value given by the
equation:
Sp; i ¼−wi’ 1–log10½e−valueð ÞR; ð1Þ
wherewi′ is the baseline relevance score for the known disease gene i′
with which the gene i is similar to. We set the weight R (R100=1 for
the gene pairs whose similarity signiﬁcance was detected with e-100)
for the cases that sequence similarity was detected by the lower sig-
niﬁcance levels (R values for e-80, 60 and 40 are given in Supplemen-
tal Table 9). When gene i does not have a similarity to any known
related gene for the disease, this score was set to be 0.
4.5. Enrichment of functional terms: disease gene functional score
Genes associated with a disease may be prioritized through their
functional similarities to known related genes for the disease or
shared physiological pathway with known related genes with the dis-
ease. Here, we have made the assumption that certain groups of
genes having related functions may be over or under-represented in
a group of genes related to a speciﬁc disease. To test this assumption,
we compared the frequencies of biological terms between the known
related genes to the target disease and all the genes in H1-REFSEQ DB.
The biological terms from the following resources were analyzed;
InterPro identiﬁers (www.ebi.ac.uk/interpro/), EC numbers (www.
chem.qmul.ac.uk/iubmb/enzyme/), KEGG pathways (www.genome.
ad.jp/kegg/) [21], and gene ontology (GO) (www.geneontology.org/
). For the known PC-related genes, “regulation of transcription,
DNA-dependent” was the most frequent among the terms in “biolog-
ical processes” of GO. However, this term was also frequent in all the
cDNAs in H1-REFSEQ DB. From the disease-speciﬁc perspective for PC,
“synaptic vesicle endocytosis” and “anti-apoptosis”, were over-
represented in the PC-related genes. As the prostate is an endocrine
organ and secretes ﬂuids, vesicle transport is an important compo-
nent of its function. Apoptosis has also been extensively studied in
cancer cells as a survival mechanism. Based on these observations
we have extended the analysis to individual genes by quantifying
and ranking the potential disease genes based on their levels of asso-
ciation to known disease-related genes through functional similarity
or linkage to common physiological pathways. To carry out these
comparisons we have utilized functional terms associated with
genes, including InterPro identiﬁers, EC numbers, and KEGG pathway
IDs, and expressed the proportion of each term for genes in the dis-
ease group compared with the frequencies among all genes in H1-
REFSEQ DB. For a given functional term j in gene annotation, a score
of relevance to the target disease was calculated by using the ratio
of the proportion of genes with the term in known disease genes to
the proportion of genes with the term in all human genes. This ratio
was multiplied by the base score of disease relevance of the term
(wj) based on curation of the known disease genes (see above).
Therefore, the score, Sf,j, was calculate by the equation
Sf ; j ¼ wj  Pd; j=Pa; j; ð2Þ
where Pd,j is the proportion of genes with the term in known disease
genes, and Pa,j is the proportion of genes with the term in all human
genes. This score was used as an indicator of the speciﬁcity of a func-
tional term in known disease genes for the target disease. For a genewhose disease relevance is unknown, the score was calculated by
summing Sf,j for all the functional terms with the gene.
4.6. Use of biological terms in gene ontology data: GO score
The gene ontology [22] is composed as “a nested hierarchical vo-
cabulary” of biological terms in which ‘general’ parent terms have
nested child terms that are more speciﬁc. We have taken advantage
of the nested hierarchy present within the GO terminology to pro-
vide a scoring system for functional speciﬁcity based on the position
of GO terms within the hierarchy. For example, cell (GO:0005623), is
a ﬁrst-level GO term under the ‘cellular component’ category, nucle-
us (GO:0005634), is a third-level term under the same category of
“cellular component”. Therefore, we gave a higher weight (Pf,j) for
a GO term j in a lower hierarchy. The score of GO term j, Sgo,j, was
calculated as a product of Ph,j and Sf,j:
Sgo; j ¼ Ph; j  Sf ; j: ð3Þ
The score of GO term for a gene was calculated as the sum of Sgo,j
for all the GO terms for the three concepts (molecular function, bio-
logical processes, and cellular components) with the gene.
4.7. Prioritization of candidates of disease-related genes by
discriminant analysis
Integration of biological information from human genes allowed
us to evaluate similarities between a given gene and multiple sets of
genes. Here, there are two groups of genes; the ﬁrst group is known
related genes to the target disease and the second group is all other
genes. For a given gene tested, a distance between the gene and the
known related genes for the target disease (group 1) was compared
with another distance between the gene and all the other genes
(group 2). To express the distance between a gene and the center of
gravity of a group of genes, the Mahalanobis distance [34] was calcu-
lated. For each gene from the group 2, we examined whether the gene
is closer to the group 1 than to the group 2 by using Mahalanobis dis-
tances and discriminant analysis. The Mahalanobis distance for a
given gene i and the group 1 (MD1) was calculated as:
MD1 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Xi−μ1ð Þ0Cov−11 Xi−μ1ð Þ
q
; ð4Þ
where Xi is a vector for gene i consisting of scores of multiple param-
eters (seven parameters in this analysis), μ1 is a vector of mean values
in the group 1, and Cov1−1 is an inverse of the covariance matrix of the
observed values of the seven parameters for the group 1. The Mahala-
nobis distance between a query gene and the group 2 (MD2) was cal-
culated in a same way. Then we judged whether a gene is closer to the
group 1 (known related genes for the target disease) than the group 2
(all the other genes). Because we consider a gene showing smaller
MD1 than MD2 to be a disease-susceptibility candidate, we calculated
the ratio of MD2 to MD1 (PANDA score). We also calculated the
PANDA score for each of known related genes to the target diseases
(the training set) in the same way, and the average score in the train-
ing set was calculated. Using the average score for the training set as a
threshold, we considered any gene to be a candidate gene of disease-
susceptibility if the score was greater than the threshold. Our results
obtained by the prioritization analysis of disease association (PANDA)
are available at http://www.h-invitational.jp/panda/app.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.ygeno.2011.10.002.
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